Abstracts tagged "Myositis"

Abstract Number: 0018 • ACR Convergence 2023
Alternative Splicing and Expected Protein Changes in Muscle Biopsies from Different Types of Idiopathic Inflammatory Myopathies
Rayan Najjar¹, Iago Pinal-Fernandez², Andrew Mammen³ and Tomas Mustelin¹, ¹University of Washington, Seattle, WA, ²National Institutes of Health, Bethesda, MD, ³NIH, Bethesda, MD
Background/Purpose: Alternative splicing of mRNA results in important biological impacts with increasing evidence implicating it in the pathology of autoimmune diseases. However, it is understudied…
Abstract Number: 0301 • ACR Convergence 2023
Inflammatory Myopathies and Their Relationship with Cancer in a Colombian Cohort
Bolaños Juan D.¹, Rivera-Londoño Robert¹, Ivana Nieto-Aristizabal¹, Karol Enriquez², Santiago Zura², Alex Echeverri¹, Andrés Hormaza-Jaramillo¹ and David Aguirre-Valencia¹, ¹Fundación Valle del Lili, Cali, Colombia, ²Universidad ICESI, Cali, Colombia
Background/Purpose: Inflammatory myopathies (IM) constitute a heterogeneous group of autoimmune muscle diseases. These can occur in isolation, associated with other autoimmune disorders, or as a…
Abstract Number: 1158 • ACR Convergence 2023
Dermatomyositis Flares After COVID-19 Vaccination and/or SARS-CoV-2 Infection
Maximiliano Diaz Menindez¹, Megan Sullivan², Benjamin Wang³, Andy Abril³, Vikas Majithia², Ronald Butendieck³, Colleen T. Ball⁴ and Florentina Berianu², ¹Mayo Clinic, Phoenix, AZ, ²Mayo Clinic Florida, Jacksonville, FL, ³Mayo Clinic, Jacksonville, FL, ⁴Mayo Clinic Jacksonville, Jacksonville, FL
Background/Purpose: Dermatomyositis (DM) is an autoimmune disorder part of the group of idiopathic inflammatory myopathies. It is characterized by proximal muscle weakness and skin involvement.…
Abstract Number: 1181 • ACR Convergence 2023
Real-World Myositis Antibody Frequency and Patient Awareness
Raisa Lomanto Silva¹, shiri keret², Akanksha Sharma³, Tanya Chandra⁴, Siamak Moghadam-Kia¹, Chester V. Oddis⁵ and Rohit Aggarwal⁵, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Bnai Zion, Atlit, Israel, ³UPMC Mercy Hospital, Pittsburgh, PA, ⁴Georgetown University Hospital, Washington, DC, ⁵University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Myositis-specific antibodies (MSA) represent unique phenotypes in idiopathic inflammatory myopathies (IIM). Myositis-associated antibodies (MAA) most commonly occur in IIM overlap syndromes. MSA and MAA…
Abstract Number: 1958 • ACR Convergence 2023
Validity, Responsiveness and Minimal Clinically Important Difference of EQ-5D-5L in Inflammatory Myositis: A Longitudinal Study
Chengappa Kavadichanda¹, Parthibane S¹, Mamatha Gorijavolu¹, Sai Kumar Dunga¹, Amrita Nayak¹, Sitanshu Sekhar¹ and Rohit Aggarwal², ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myositis (IIM) significantly impacts health-related quality of life (HRQoL). EQ5D-5L is a widely used and validated tool to measure HRQoL. The health…
Abstract Number: 2466 • ACR Convergence 2023
Monoclonal Anti-MDA5 Autoantibodies Derived from a Patient with Dermatomyositis Target the Hel2i Domain of the MDA5 Protein
Eveline Van Gompel¹, Ragnhild Stålesen², Caroline Grönwall², Annika van Vollenhoven², Lena Israelsson², Ingrid Lundberg³, Vivianne Malmström², Karine Chemin⁴ and Vijay Joshua², ¹Karolinska Institutet - KU Leuven, Leuven, Belgium, ²Karolinska Institutet, Stockholm, Sweden, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ⁴Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The strong clinical association between the anti-MDA5 autoantibodies and the development of severe lung disease in patients with dermatomyositis (DM) suggests an active role…
Abstract Number: 0126 • ACR Convergence 2023
Epidemiology and Retrospective Case-Control Analysis of IIM in the US Veteran Population
Vladimir Liarski, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) - comprising polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM) - is rare and difficult to study. We sought…
Abstract Number: 0302 • ACR Convergence 2023
Remission in Anti-HMGCR Positive Immune-mediated Necrotizing Myopathy Without the Use of Glucocorticoids: A Multicentric Study of 24 Patients
David Martinez-Lopez¹, Cristina Corrales Selaya², Diana Prieto-Peña², Piotr Szczesny³, Antonella Notarnicola⁴, Ricardo Blanco⁵, Ingrid Lundberg⁶ and Maryam Dastmalchi⁶, ¹Hospital de Sierrallana, Santander, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Department of Rheumatology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, Poland; Department of Neurology, Medical University of Warsaw, Warsaw, Poland, ⁴Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁵Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden
Background/Purpose: Statin-induced immune mediated necrotizing myopathy (IMNM) is a subtype of inflammatory myopathy associated with anti-3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) autoantibodies. This condition is characterized by progressive…
Abstract Number: 1159 • ACR Convergence 2023
Expanded Cytotoxic CD8+ T Cell Clones Characterize the Blood of Inclusion Body Myositis Patients
Miriam Fein¹, Laura Donlin¹, David Fernandez¹ and Lorien Shakib², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Inclusion body myositis (IBM) is an inflammatory myopathy, characterized by CD8+ T cell infiltration of muscle and patients present with progressive muscle weakness and…
Abstract Number: 1182 • ACR Convergence 2023
Treatment Trajectories and Patient Outcomes in Idiopathic Inflammatory Myopathies
Kristin Wipfler¹, Michael Feely², Gulsen Ozen³, Urbano Sbarigia⁴, Federico Zazzetti⁵, Anna Sheahan⁶, Iris Lin⁷, Evo Alemao⁸ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Bellevue, NE, ⁴Janssen Pharmaceutica, Beerse, Belgium, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Janssen, Raleigh, NC, ⁷Janssen, Horsham, PA, ⁸Janssen Pharmaceuticals, New Hope, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare, heterogeneous diseases characterized by chronic skeletal muscle inflammation and weakness. Initial conventional therapy is based on expert opinion…
Abstract Number: 1959 • ACR Convergence 2023
Quantitative Scoring of High Resolution Chest Computed Tomography (HRCT) Images in Myositis and Antisynthetase Syndrome Related Interstitial Lung Disease in Comparison to Scleroderma Related Interstitial Lung Disease
Sangmee Bae¹, Fereidoun Abtin², Grace Kim³, Siamak Moghadam-Kia⁴, Chester V. Oddis⁵, Lila Pourzand², Didem Saygin⁵, Daniel Sullivan⁶, Koichi Yamaguchi⁷, Donald Tashkin³, Christina Charles-Schoeman⁸, Jonathan Goldin³ and Rohit Aggarwal⁵, ¹UCLA Rheumatology, Los Angeles, CA, ²UCLA Radiological Sciences, Los Angeles, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴University of Pittsburgh Medical Center, Pittsburgh, PA, ⁵University of Pittsburgh, Pittsburgh, PA, ⁶UCLA Pulmonology, Pittsburgh, PA, ⁷University of Pittsburgh Medical Center Rheumatology, Pittsburgh, PA, ⁸UCLA Medical Center, Santa Monica, CA
Background/Purpose: High resolution computed tomography (HRCT) of the chest has become an important modality in the evaluation of interstitial lung disease (ILD). A quantitative CT…
Abstract Number: 2514 • ACR Convergence 2023
Myositis Triad Subset Is Associated with High Mortality in Immune Checkpoint Inhibitor- Induced Myositis
Selene Rubino¹, Grant Cannon², Brian Sauer³, Jorge Rojas Jr⁴, Greg Stoddard¹, Gary Kunkel¹, Jessica A Walsh⁵, Bryant England⁶, Ted R Mikuls⁷, Joshua Baker⁸ and Tawnie Braaten¹, ¹University of Utah, Salt Lake City, UT, ²University of Utah and Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁴Puget Sound VA and University of Utah, Seattle, WA, ⁵Salt Lake City Veterans Affairs Health and University of Utah Health, Division of Rheumatology, Salt Lake City, UT, ⁶University of Nebraska Medical Center, Omaha, NE, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Myositis is an infrequent but serious complication associated with immune check point inhibitor (ICI) treatment. Many patients with ICI-induced myositis will develop concurrent myocarditis…
Abstract Number: 0150 • ACR Convergence 2023
Self-reported Levels of Physical Activity and the Association to Pain, Fatigue, Anxiety and Depression Among Patients with Idiopathic Inflammatory Myopathies
Kristofer Andreasson¹, Fabricio Espinosa-Ortega², Heléne Sandlund³ and Helene Alexanderson⁴, ¹Karolinska Institutet & Karolinska University Hospital, Stockholm, Sweden, ²Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden, ³Karolinska University Hospital, Stockholm, Sweden, ⁴Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Patients with inflammatory diseases such as rheumatoid arthritis exhibit reduced levels of physical activity (PA) compared to the normative population and suffer from anxiety…
Abstract Number: 0303 • ACR Convergence 2023
Development of a Human Cytotoxic Myoinjury Model with CD8+ T Cells and Muscle Cells Differentiated from Human Induced Pluripotent Stem Cells
Hisanori Hasegawa¹, Soki Kashima², Makoto Otsu³, Hideki Taniguchi⁴ and Shinsuke Yasuda⁵, ¹Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU) and Institute of Global Affairs, Tokyo Medical and Dental University (TMDU), Tokyo, Japan, ²Laboratory of Immunology, Institute for Life and Medical Sciences, Kyoto University and Department of Urology, Akita University Graduate School of Medicine, Akita, Japan, ³Division of Hematology, Department of Laboratory Sciences, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan, ⁴Division of Stem Cell Processing/Stem Cell Bank, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, Tokyo, Japan, ⁵Department of Rheumatology, Graduate School of Medical and Dental Science, Tokyo Medical and Dental University (TMDU), Tokyo, Japan
Background/Purpose: CD8+ cytotoxic lymphocytes (CTLs) play a crucial role in the myoinjury of polymyositis (PM). Nonetheless, conventional treatment for PM depends on high-dose glucocorticoids with…
Abstract Number: 1160 • ACR Convergence 2023
Antibody Predictors of Prognosis in a Large Multi-centre Cohort of Idiopathic Inflammatory Myopathy Associated Interstitial Lung Disease
Jennifer Hannah¹, Alexandra Lawrence², Jennifer Martinovic², Marium Naqvi², Saadia Sasha Ali³, Carmel Stock⁴, Cara Owens⁴, Anand Devaraj⁴, Louise Pollard², Sangita Agarwal², Belén Atienza-Mateo⁵, Amit Patel⁶, Alex West², Kate Tinsley², Hasti Robbie⁷, Felix Chua⁴, Boris Lams², Athol Wells⁴, Sam Norton⁷, James Galloway⁷, Elisabetta Renzoni⁴ and Patrick Gordon⁸, ¹King's College London, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ³King's College Hospital, Epsom, United Kingdom, ⁴Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom, ⁵Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁶King's College Hospital, London, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸NHS, London, United Kingdom
Background/Purpose: IIM-ILD follows a varied clinical course. Serological profile can help predict clinical phenotype, but impact on ILD prognosis is less clear. This multicentre UK…

« Previous Page
1
…
6
7
8
9
10
…
28
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.